Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and molecular response to vorasidenib in post-transplant patient with IDH2-mutant intrahepatic cholangiocarcinoma.

The oncologist - 6 Jun 2026

Altiery De Jesus Vivian V, McMahon Timothy, Young Sara E, Zabransky Daniel J, Yarchoan Mark, Baretti Marina

Abstract excerpt

BACKGROUND: IDH2 mutations occur in a small subset of intrahepatic cholangiocarcinoma and currently lack approved targeted therapies. CASE PRESENTATION: We report a post-transplant patient with IDH2-mutant intrahepatic cholangiocarcinoma who developed recurrent disease following multiple treatments for hepatocellular carcinoma and subsequent liver transplantation. Comprehensive genomic profiling revealed an IDH2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bile Duct Neoplasms
Share to Cholangiocarcinoma

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to IDH1 gene

Share to IDH2 gene

Share to Isocitrate Dehydrogenase

Share to Liver Transplantation

Share to Mutation

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 42286810
DOI: 10.1093/oncolo/oyag228
PMCID: PMC13310476

Genes

IDH2
IDH1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and molecular response to vorasidenib in post-transplant patient with IDH2-mutant intrahepatic cholangiocarcinoma.PMID 42286810Read ↗

Comprehensive Immunogenomic Profiling of IDH1-/2-Altered Cholangiocarcinoma.Semantic proximity Read ↗

Association of IDH1 mutations with survival and recurrence in resected intrahepatic cholangiocarcinoma received or not received adjuvant chemotherapy.Semantic proximity Read ↗

IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment—Current State and Future PerspectivesSemantic proximity Read ↗

Evaluating the Prognostic Impact of IDH Mutations in Intrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions.Semantic proximity Read ↗

Impact of IDH1 mutation on clinical course of patients with intrahepatic cholangiocarcinoma: a retrospective analysis from a German tertiary center.Semantic proximity Read ↗

IDH Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients.Semantic proximity Read ↗

Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.Semantic proximity Read ↗

MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the IFN Response.Semantic proximity Read ↗

Clinical development of IDH1 inhibitors for cancer therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.